17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

Bagacean, C; Tempescul, A; Ternant, D; Banet, A; Douet-Guilbert, N; Bordron, A; Bendaoud, B; Saad, H; Zdrenghea, M; Berthou, C; Paintaud, G; Renaudineau, Y

Bagacean, C (reprint author), Univ Brest, U1227 B Lymphocytes & Autoimmun, INSERM, Networks IC CGO Canceropole Grand Ouest, Brest, France.; Bagacean, C (reprint author), Univ Brest, U1227 B Lymphocytes & Autoimmun, INSERM, Network REpiCGO Canceropole Gran

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019; 7 ():

Abstract

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic go......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索